Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Trial Profile

Multi-Center, Open-Label, Randomized Study of Anti-CCR4 Monoclonal Antibody KW-0761 or Investigator's Choice in Subjects With Previously Treated Adult T-cell Leukemia-Lymphoma (ATL)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 28 Dec 2017

At a glance

  • Drugs Mogamulizumab (Primary)
  • Indications Adult T-cell leukaemia-lymphoma
  • Focus Registrational; Therapeutic Use
  • Sponsors Kyowa Hakko Kirin
  • Most Recent Events

    • 20 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Jan 2018.
    • 26 Jan 2017 Planned End Date changed from 1 Nov 2016 to 1 Dec 2017.
    • 06 Dec 2016 Results (data cut off, 31 March 2016) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top